相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P. A. Fasching et al.
ANNALS OF ONCOLOGY (2021)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy
Rayhaan M. M. Ali et al.
GENES CHROMOSOMES & CANCER (2021)
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
Pascal Pujol et al.
EUROPEAN JOURNAL OF CANCER (2021)
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M. Swisher et al.
NATURE COMMUNICATIONS (2021)
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.
Jennifer Keating Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Comparison of BRCA versus non-BRCA germline mutations and is associated somatic mutation profiles in patients with unselected breast cancer
Bo Chen et al.
AGING-US (2020)
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A. G. Waks et al.
ANNALS OF ONCOLOGY (2020)
The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort
Chunling Hu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors
Jacob Rinaldi et al.
PLOS ONE (2020)
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Neha Chopra et al.
NATURE COMMUNICATIONS (2020)
Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls
Supriya Behl et al.
SCIENTIFIC REPORTS (2020)
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes
Solene De Talhouet et al.
SCIENTIFIC REPORTS (2020)
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
E. L. Mayer et al.
ANNALS OF ONCOLOGY (2020)
Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
Jiande Wu et al.
CANCERS (2020)
ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor plus palbociclib (AI plus P) for metastatic breast cancer (MBC) in the PADA-1 trial
J-S. Frenel et al.
ANNALS OF ONCOLOGY (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Homologous repair deficiency score for identifying breast cancers with defective DNA damage response
Ahrum Min et al.
SCIENTIFIC REPORTS (2020)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2-) advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA1/2) mutation
Jennifer K. Litton et al.
CANCER RESEARCH (2020)
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
Joyce O'Shaughnessy et al.
BREAST CANCER RESEARCH (2020)
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J. K. Litton et al.
ANNALS OF ONCOLOGY (2020)
Pan-cancer landscape of homologous recombination deficiency
Luan Nguyen et al.
NATURE COMMUNICATIONS (2020)
BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
Esther H. Lips et al.
BREAST CANCER RESEARCH (2020)
Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing
Katherine Vlessis et al.
JNCI CANCER SPECTRUM (2020)
Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort
Jingmei Li et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
Joshua James Gruber et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status
Kimmie McLaurin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).
Anne Patsouris et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients
Allison W. Kurian et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Tumour lineage shapes BRCA-mediated phenotypes
Philip Jonsson et al.
NATURE (2019)
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
Lindsay Angus et al.
NATURE GENETICS (2019)
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Johan Staaf et al.
NATURE MEDICINE (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
Mark Robson et al.
EUROPEAN JOURNAL OF CANCER (2019)
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
Nicholas C. Turner et al.
CLINICAL CANCER RESEARCH (2019)
Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Peter D. Beitsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank
Noura S. Abul-Husn et al.
GENOME MEDICINE (2019)
Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
Adam Poti et al.
GENOME BIOLOGY (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review
K. J. Jerzak et al.
CURRENT ONCOLOGY (2018)
Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial
J. Ettl et al.
ANNALS OF ONCOLOGY (2018)
Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA plus ).
Jennifer Keating Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma
Aparna Gorthi et al.
NATURE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo et al.
EMBO MOLECULAR MEDICINE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants
Kandamurugu Manickam et al.
JAMA NETWORK OPEN (2018)
Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients
Y. Xie et al.
CLINICAL GENETICS (2018)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer
Robert W. Mutter et al.
JOURNAL OF PATHOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
Paz Polak et al.
NATURE GENETICS (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients
Hiroji Iwata et al.
JOURNAL OF GLOBAL ONCOLOGY (2017)
Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity
Bose S. Kochupurakkal et al.
CANCER RESEARCH (2017)
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers
Julia Krammer et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk
Thomas P. Slavin et al.
NPJ BREAST CANCER (2017)
A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes
Saundra S. Buys et al.
CANCER (2017)
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
C. Winter et al.
ANNALS OF ONCOLOGY (2016)
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal et al.
NATURE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms
Philip C. Schouten et al.
MOLECULAR ONCOLOGY (2015)
Frequency of Mutations in Individuals With Breast Cancer Referred for BRCA1 and BRCA2 Testing Using Next-Generation Sequencing With a 25-Gene Panel
Nadine Tung et al.
CANCER (2015)
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Ilirjana Bajrami et al.
CANCER RESEARCH (2014)
Breast-Cancer Risk in Families with Mutations in PALB2
A. C. Antoniou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
Marieke A. Vollebergh et al.
BREAST CANCER RESEARCH (2014)
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Kirsten M. Timms et al.
BREAST CANCER RESEARCH (2014)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
V. Abkevich et al.
BRITISH JOURNAL OF CANCER (2012)
Clinical significance of large rearrangements in BRCA1 and BRCA2
Thaddeus Judkins et al.
CANCER (2012)
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Nasim Mavaddat et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
Tatiana Popova et al.
CANCER RESEARCH (2012)
Use of the MLPA Assay in the Molecular Diagnosis of Gene Copy Number Alterations in Human Genetic Diseases
Liborio Stuppia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Nicolai J. Birkbak et al.
CANCER DISCOVERY (2012)
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
M. A. Vollebergh et al.
ANNALS OF ONCOLOGY (2011)
DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Shadia Jalal et al.
CLINICAL CANCER RESEARCH (2011)
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness
Esther H. Lips et al.
BREAST CANCER RESEARCH (2011)
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years
Kathleen E. Malone et al.
CANCER RESEARCH (2006)
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
Anthony Renwick et al.
NATURE GENETICS (2006)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women
MR McClain et al.
GENETICS IN MEDICINE (2005)
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer
P Vahteristo et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
M Esteller et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
